Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma
| Autor: | Gregory M. Cote, Robert A. Redd, Ann S. LaCasce, Donna Neuberg, Olga Pozdnyakova, Ephraim P. Hochberg, Arnold S. Freedman, David M. Dorfman, David C. Fisher, Paola Dal Cin, Eric D. Jacobsen, Ali Shahsafaei, Philippe Armand, Jennifer R. Brown |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Cancer Research Pathology medicine.medical_specialty Platelet-derived growth factor Receptor Platelet-Derived Growth Factor alpha Oncogene Proteins Fusion Antineoplastic Agents Disease-Free Survival chemistry.chemical_compound Recurrence hemic and lymphatic diseases medicine Humans neoplasms In Situ Hybridization Fluorescence Aged Aged 80 and over mRNA Cleavage and Polyadenylation Factors medicine.diagnostic_test business.industry Not Otherwise Specified Lymphoma T-Cell Peripheral Imatinib Hematology Middle Aged medicine.disease Immunohistochemistry Peripheral T-cell lymphoma Lymphoma Imatinib mesylate Treatment Outcome Oncology chemistry Drug Resistance Neoplasm embryonic structures cardiovascular system Cancer research Imatinib Mesylate Female business Fluorescence in situ hybridization medicine.drug Follow-Up Studies |
| Zdroj: | Leukemialymphoma. 56(4) |
| ISSN: | 1029-2403 |
| Popis: | Platelet derived growth factor-α (PDGFR-α) is expressed in peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Imatinib mesylate demonstrated in vitro cytotoxicity against primary PTCL, NOS cells. We initiated a trial of imatinib in 12 patients with relapsed or refractory T-cell non-Hodgkin lymphoma (T-NHL). PDGFR-α expression by immunohistochemistry and fluorescence in situ hybridization (FISH) to assess for FIP1L1-PDGFR-α fusion and/or PDGFR-α amplification were not required for study entry. We documented no objective responses. The median progression-free survival was 21.0 days (90% confidence interval [CI] 15.0, 28.0) and median overall survival was 154 days (90% CI 35, 242). Four patients had tissue available for analysis of PDGFR-α by immunohistochemistry and three of these patients' tumors expressed PDGFR-α. Imatinib was not effective for the treatment of peripheral T cell lymphoma in an unselected group of patients in which PDGFR-α expression was not required for study entry. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|